Table 3.
Evaluation biomarker signature (CCL1, CXCL10, VEGF, and ADA2 or total ADA) in distinguishing ATB from untreated LTBI.
| CCL1, CXCL10, VEGF, and ADA2 | CCL1, CXCL10, VEGF, and total ADA | |
|---|---|---|
| AUC | 0.9525 | 0.9475 |
| Coefficients | ||
| Intercept | -12.0204 | -10.1068 |
| Log10 CCL1 | 6.0145 | 6.4648 |
| Log10 CXCL10 | -3.0394 | -3.5797 |
| Log10 VEGF | 3.4635 | 3.2062 |
| ADA2 | 0.9583 | NA |
| Total ADA | NA | 0.5903 |
| Optimal Cutoff | >0.5099783 | >0.4499695 |
| Discovery cohort | ||
| Sensitivity (%) | 95 | 100 |
| Specificity (%) | 90 | 90 |
| Leiden cohort | ||
| Sensitivity (%) | 75 | 67 |
| Specificity (%) | 100 | 100 |
| Italy cohort | ||
| Sensitivity (%) | 100 | 100 |
| Specificity (%) | 30 | 20 |
CCL, C-C motif chemokine ligand 1; CXCL10, C-X-C motif chemokine ligand 10; VEGF, vascular endothelial growth factor; ADA2, adenosine deaminase 2 activity; total ADA, total adenosine deaminase activity; AUC, area under the curve; NA, not applicable.